Background: Irinotecan is currently used as second-line chemotherapy for advanced colorectal cancer. We report a case of severe thrombocytopenia after Irinotecan, suggesting an immune mechanism, in a 53-year-old patient.
Introduction
Irinotecan (Campto®) is a camptothecin derivative registered for the treatment of advanced 5-fluorouracil (5-FU) pretreated colorectal cancer. It acts through the inhibition of DNA topoisomerase I. Its treatment-limiting side effects are leukoneutropenia and diarrhea [1] [2] [3] [4] [5] .
Here we report a case of severe thrombocytopenia in which history and laboratory studies demonstrate an immune mechanism involving Irinotecan.
later showed severe thrombocytopenia (7 x 10 9 /l), with no other hematological abnormalities or evidence of hemolysis or disseminated intravascular coagulation. Bone marrow aspirate was normal. Antibiotics were stopped. The platelet count returned to normal range within five days.
A second Irinotecan infusion was administered 28 days later with normal blood cell count values, after the same premedication plus corticosteroids and antihistamines. At the 100th minute of the infusion, back and Case report A 53-year-old man had a sigmoidectomy in January 1994 followed by bolus 5-FU and folinic acid for a Dukes D colon adenocarcinoma with liver metastases. In November 1994, progression led to chemotherapy with chronomodulated 5-FU/folinic acid infusion and oxaliplatin (100 mg/m 2 , Eloxatine®). In August 1995, after a major response, he underwent a hepatic metastasectomy with right portal embolization, followed by six cycles of 5-FU and folinic acid. Irinotecan was initiated in November 1995 due to hepatic recurrence. Pretherapeutic blood cell counts were normal. The first cycle was administered as a 350 mg/m 2 120-minute infusion, preceded by atropine and Granisetron. At the 100th minute of the infusion, the patient experienced hypotension, shivering, vomiting, cyanosis and hyperthermia. Irinotecan was discontinued, and wide-spectrum antibiotherapy with ceftazidim and amikacin was started. The fever decreased rapidly. Blood cell counts performed 18 hours /l) six hours later. Corticosteroids were given for 48 hours and the platelet count returned to normal range over four days.
the absence of the commercially available Irinotecan (concentration 116,4 ug/ml) and in some experiments with its native form and its active metabolite SN-38. Finally, to demonstrate the patient's platelet antibody fixation specificity, the same experiments were performed with patient sera in the presence of the drug but after FcRyRII blockade with a CD32 MoAb (IV-3, Medarex) as previously described [11] .
Patients and methods
Cell and serum preparation Sera were obtained six hours after the second episode of thrombocytopenia and again seven months later. Platelets from group O healthy blood donors, a patient with Glanzmann thrombasthenia, and from the patient were isolated by differential centrifugation of EDTA-and ACD-anticoagulant whole blood. Polyclonal antibodies from alloimmunized patients locally shown to recognize human platelet alloantigens were used to phenotype platelet suspensions, or as positive control. Serum from untransfused healthy male group AB donors served as negative controls. Sera from five non-thrombocytopenic patients receiving Irinotecan were also tested as controls.
Antibody identification
Sera were screened for HLA. granulocyte and red blood cell antibodies by means of the standard lymphocytotoxicity test [6] , the granuloimmunofluorescence test [7] and a standard indirect antiglobulin test, respectively.
Platelet antibodies were sought by means of a platelet indirect immunofluorescence test (PIIFT) using fluorescein isothianate F(ab)'2 rabbit anti-human IgG and IgM (Dakopatts. Copenhagen, Denmark) [8] . Sera were tested against a panel of phenotyped platelets selected to present all possible phenotypes in the HPA 1-3-5 alloantigen systems, against the patients' own platelets collected after platelet remission and against platelets from a patient with Glanzmann's thrombasthenia totally deficient of Gp Ilb/IIIa. Results were graded from -to ++++ by comparison with the negative and the positive control. Serum platelet antibody was also sought by means of immunoblotting [9] and the monoclonal antibody (MoAb) immobilization of platelet antigens assay (MAIPA) [7] using a peroxidase-labelled goat anti-human Fc IgG (Jackson). In the MAIPA assay. CD4I/61 (P2. S222, S221. Immunotech and AP2. GTI). CD42 (FMC25, Serotec, SZ2, SZ1. Immunotech and MB45. Tebu). CD49 (G19. Immunotech), CD62 (S12. Centocor). CD36 (FA6-152. Immunotech). CD9 (Alb6. Tebu) and CD31 (SG134) MoAbs were used to characterize the patient's antibody fixation site.
In each immunoassay. the granuloimmunofluorescence and indirect antiglobulin tests, patient sera were tested in the presence and
Results
No HLA, granulocyte or red blood cell antibodies were detected in the patient sera. No platelet antibodies were found using PIIFT when Irinotecan was not added in the reaction. However, when commercially available Irinotecan was added, an IgG with strong platelet membrane reactivity (+++) was found. The antibody recognized all of the platelet suspensions tested. The same results were obtained in the PIIFT when the native form of Irinotecan was added in the reaction, but no platelet antibody was found when SN-38 was added. No drug-dependent platelet antibody was found in the patient serum collected seven months after the second episode of thrombocytopenia, nor in sera from the five non-thrombocytopenic patients receiving Irinotecan. The platelet antibody fixation specificity was confirmed by blocking experiments since the same results were obtained when CD32 MoAb was added, and no antibody was found with granuloimmunofluorescence and indirect antiglobin test. However, the target of the platelet antibody was not identified in the MAIPA assay with the monoclonal antibodies used, nor with immunoblotting (Table 1) .
Discussion
The toxic effects of Irinotecan are cholinergic symptoms, diarrhea and hematology. Severe grade 3-4 thrombocytopenia was observed between 10 and 15 days after the drug's administration in about 6% of patients, usually associated with leukoneutropenia, suggesting impaired platelet production [1] [2] [3] [4] [5] .
We describe here a case of Irinotecan-induced severe isolated thrombocytopenia. The immune mechanism is supported by its temporal relationship with Irinotecan administration; it recovered after Irinotecan interruption and reappeared after Irinotecan rechallenge; other causes of thrombopenia are ruled out and laboratory tests clearly demonstrated the presence of an Irinotecandependent platelet-reactive IgG antibody that specifically bound platelets via its F(ab)'2 fragment, only in the presence of this drug. A responsibility of the other administered drugs cannot be strictly ruled out; they are not known to induce immune thrombocytopenia, and laboratory studies demonstrate the absence of vancomycin-dependent antibody (data not shown).
Many drugs have been described as inducing immune thrombocytopenia. Several mechanisms are proposed according to drug fixation. First, it was proposed that the primary reaction might be a combination of the drug with the antibody, with secondary adsorption of the antibody-drug complex to the platelets via their IgG Fc receptors. Experimental data proposed an alternative mechanism in which the drug combined with specific platelet component leads to a reversible neoantigenic platelet-drug complex binding the antibody [11] [12] [13] [14] [15] . Our case supports the latter mechanism. However, the occurrence of the thrombocytopenia after the first administration of Irinotecan is unusual. One explanation could be that the responsible antibody could recognize a crossreactive antigen between Irinotecan and another molecule previously administered. Another unusual aspect of our observation is the fact that immunoblotting and MAIPA assay failed to identify the platelet binding site when drug-dependent antibody previously characterized binds GpIIb/IIIa or GpIb/IX [11, [13] [14] [15] . Furthermore, our results with Glanzmann platelets confirmed that GpIIb/IIIa is not the target, which suggests that an antibody target epitope would be dependent on conformational changes in the Gp that bind the platelet antibody. The dru-dependent platelet antibody did not bind platelets in the presence of SN-38, suggesting that the moiety responsible for the immune reaction might be the piperidino-piperidin fragment of Irinotecan which, when released by serum carboxylesterase, results in SN-38, the metabolite with clinical antitumor activity.
In conclusion, this is the first report of a documented case of Irinotecan-induced immune thrombocytopenia. Immune Irinotecan thrombocytopenia might be observed more frequently in future, with increased prescription patterns.
